By Nigam Arora 215 Buyouts — A New Record of Success for Arora Members Avidity Biosciences (RNA) has received a buyout offer from Novartis (NVS) for approximately $12B. RNA is the 215th Arora Portfolio company to be bought out. This milestone demonstrates the strength of The Arora Report’s approach. Neuromuscular Diseases
This post was just published on ZYX Short Change Alert. Partial profits have previously been taken on RNA, only 5% of the full core position size is left, and now it is running approaching our entry price. The stock is volatile and at $10.26 as of this writing. Consider taking profits and exiting
This post was just published on ZYX Short Change Alert. RNA is short from $10.50. As of this writing RNA is trading at $7.87. 20% of the full core position size is being held. Consider taking profits on a 15% tranche in the zone of $7.15 to $7.95. Consider continuing to
This post was just published on ZYX Short Change Alert. RNA is again falling to under $10. Mental stop zone now is $14.00 15.56. This is a very volatile stock suitable only for aggressive investors. Target zone is $4.00-4.50. The probability of its treatment ultimately getting approval is small. What to
This post was just published on ZYX Short Change Alert. RNA is a development stage biotech company. Until yesterday shares had moved up in sympathy with the success at PTCT. Today’s shares are moving up strongly again as investors react to company releasing its presentation to be made at Jeffries on